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‘Crystal’ in the heart
„Kryształ” w sercu
Stephan Wiedemann1, Uwe Speiser1, Reinhard Kandolf2, Ruth H. Strasser1
1Department of Cardiology, University of Dresden, Heart Centre, Dresden, Germany 
2Department of Molecular Pathology, Institute for Pathology and Neuropathology, University Hospital, Eberhard Karls University,  
Tuebingen, Germany
A 35-year-old man presented to the emergency unit with progres-
sive dyspnoea of two weeks’ duration. He had no previous medical 
history, and denied chest discomfort. During echocardiography, 
a severely impaired biventricular systolic function with severe 
atrioventricular valve insufficiency was found. The left ventricular 
end diastolic diameter (LVEDD) was 74 mm (Fig. 1A). There was no 
evidence of coronary artery disease (CAD), as shown in Figure 1B. 
On inquiry, he confessed to a weekly consumption of ‘crystal’ 
(methyl amphetamine) of about 0.5–1 g. Haemodynamic find-
ings showed a decreased cardiac index of 1.7 L/min/m2. The 
patient had an intra-aortic balloon pump implanted as a bridge 
to recovery. However, haemodynamic and echocardiographic 
parameters did not improve, so he received a levosimendan infu-
sion. Left ventricular endomyocardial biopsies were taken, and 
histological and immunohistological examinations revealed severe 
methamphetamine-induced chronic myocardial injury with degen-
eration of hypertrophied myocytes neighbouring small arterioles 
with medial hyperplasie in the presence of a mild inflammatory 
reaction (Fig. 1D). There was no evidence of acute or chronic 
myocarditis, amyloidosis or preexisting dilated or other primary 
cardiomyopathies. No viral genomes were detected by nested PCR 
analysis. The results were confirmed by cardiac magnetic resonance 
imaging (MRI) (Fig. 1C). Late gadolinium enhancement indicating 
myocardial fibrosis or necrosis was not obvious. The patient slowly 
recovered over the course of two weeks. Long-term ECG showed 
a non-sustained ventricular tachycardia of 18 beats. He left hospital 
with a wearable cardioverter-defibrillator (LifeVest®). Chronic use of 
methyl amphetamine may result in severe heart failure, malnutri-
tion, infections and permanent psychiatric illness. The patient was 
discharged for outpatient drug rehabilitation.
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Figure 1. A. Echocardiography showed severely impaired biventricular systolic function (LVEF and RVEF 15%) with severe 
tricuspid and mitral valve insufficiency; A1. Apical four-chamber view showed the globally poor myocardial contractility in 
biventricular dilatated heart; A2. Parasternal long axis view showed enlarged LVEDD (74 mm); B. Coronary angiographic 
findings without evidence of CAD; B1. Right coronary artery; B2. Left main with Ramus circumflexus and Ramus interven-
tricularis anterior; C. Cardiac MRI showed a severely impaired left and right ventricular function without evidence of late 
gadolinium enhancement; C1. Fiesta four-chamber view Asset; C2. Fiesta SA Asset; D. Histology and immunohistology (IH) 
of methamphetamine-induced cardiomyopathy; D1. Severe chronic myocardial injury with degeneration of hypertrophied 
myocytes and interstitial fibrosis in the vicinity of a hypertrophied arteriole (Masson trichrome, × 100); D2. HLA class II 
expression in professional antigen-presenting immune cells and in endothelial cells of small vessels (IH, × 400); D3. Pro-
liferating smooth muscle cells within the media of a hypertrophied arteriole with luminal constriction (IH, × 200)
